Minjuvi (Tafasitamab)

Tafasitamab targets the CD19 protein on the surface of B‑cells. By binding to CD19, it activates antibody‑dependent cellular cytotoxicity, recruiting immune cells to destroy the malignant B‑cells, and also triggers direct apoptotic pathways within the tumor cells.

The dosing schedule for Minjuvi is determined by the prescribing oncologist based on the patient’s clinical status, body weight, and combination with lenalidomide. Specific dose and infusion frequency are individualized and should follow the approved prescribing information.

Safety data for Minjuvi during pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and risk with their healthcare provider.

To place an order, submit an enquiry on the Minjuvi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any required import documentation.

The primary alternative for CD19‑targeted treatment is CAR‑T cell therapy, which involves patient‑specific cell engineering. Minjuvi offers an off‑the‑shelf monoclonal antibody option that can be administered more rapidly, without the need for individualized cell manufacturing, but may have a different safety and efficacy profile.

Minjuvi must be stored refrigerated at 2‑8 °C. The vials should be kept in their original packaging, protected from light, and must not be frozen or shaken. Prior to infusion, the solution should be inspected for particulate matter and discoloration.

Minjuvi is administered as an intravenous infusion. The infusion is typically performed in a clinical setting by qualified healthcare professionals, with monitoring for infusion‑related reactions during and after the administration. The exact infusion rate and duration are defined by the prescribing information.

Serious adverse events include severe infections, hepatotoxicity, hypersensitivity reactions such as anaphylaxis, and tumor lysis syndrome. Patients should be closely monitored for signs of infection, liver dysfunction, allergic responses, and metabolic abnormalities during treatment.

Minjuvi is contraindicated in patients with known hypersensitivity to tafasitamab or any excipients in the formulation. It should also be avoided in individuals receiving live vaccines or those with uncontrolled active infections until the infection is resolved.